About Lisata Therapeutics, Inc.
https://www.lisata.comLisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.
CEO
David J. Mazzo
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-15 | Reverse | 1:15 |
| 2016-07-28 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:270.51K
Value:$562.67K
RENAISSANCE TECHNOLOGIES LLC
Shares:116.62K
Value:$242.57K
BML CAPITAL MANAGEMENT, LLC
Shares:109.84K
Value:$228.47K
Summary
Showing Top 3 of 25
About Lisata Therapeutics, Inc.
https://www.lisata.comLisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $4.41M ▼ | $-4.25M ▲ | 0% ▲ | $-0.49 ▲ | $-4.21M ▲ |
| Q2-2025 | $70K ▲ | $4.94M ▼ | $-4.66M ▲ | -6.66K% ▼ | $-0.54 ▲ | $-4.62M ▲ |
| Q1-2025 | $0 ▼ | $5.85M ▼ | $-4.72M ▼ | 0% ▲ | $-0.55 | $-5.8M ▼ |
| Q4-2024 | $1M ▲ | $5.95M ▲ | $-4.61M ▲ | -461% ▼ | $-0.55 ▲ | $-4.91M ▲ |
| Q3-2024 | $0 | $5.34M | $-4.93M | 0% | $-0.59 | $-5.29M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $19M ▼ | $21.76M ▼ | $4.64M ▲ | $17.37M ▼ |
| Q2-2025 | $21.97M ▼ | $25.16M ▼ | $4.38M ▲ | $21.03M ▼ |
| Q1-2025 | $25.83M ▼ | $28.98M ▼ | $3.88M ▼ | $25.36M ▼ |
| Q4-2024 | $31.25M ▼ | $35M ▼ | $5.68M ▲ | $29.57M ▼ |
| Q3-2024 | $35.86M | $38.2M | $4.76M | $33.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.25M ▲ | $-3.34M ▲ | $5.15M ▲ | $353K ▲ | $2.16M ▲ | $-3.34M ▲ |
| Q2-2025 | $-4.66M ▲ | $-3.96M ▲ | $505K ▼ | $64K ▲ | $-3.38M ▼ | $-3.98M ▲ |
| Q1-2025 | $-4.72M ▼ | $-5.4M ▼ | $9.43M ▲ | $-23K ▲ | $4.01M ▲ | $-5.43M ▼ |
| Q4-2024 | $-4.61M ▲ | $-4.53M ▼ | $1.39M ▲ | $-96K ▼ | $-3.3M ▲ | $-4.53M ▼ |
| Q3-2024 | $-4.93M | $-2.52M | $-6.3M | $0 | $-8.78M | $-2.52M |
CEO
David J. Mazzo
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-15 | Reverse | 1:15 |
| 2016-07-28 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:270.51K
Value:$562.67K
RENAISSANCE TECHNOLOGIES LLC
Shares:116.62K
Value:$242.57K
BML CAPITAL MANAGEMENT, LLC
Shares:109.84K
Value:$228.47K
Summary
Showing Top 3 of 25